A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors
- 1 September 2007
- journal article
- research article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 14 (3), 887-900
- https://doi.org/10.1677/erc-07-0062
Abstract
Although most pituitary tumors are benign, some are invasive or aggressive. In the absence of specific markers of malignancy, only tumors with metastases are considered malignant. To identify markers of invasion and aggressiveness, we focused on prolactin (PRL) tumors in the human and rat. Using radiology and histological methods, we classified 25 human PRL tumors into three groups (non-invasive, invasive, and aggressive–invasive) and compared them with a model of transplantable rat PRL tumors with benign and malignant lineages. Combining histological(mitoses and labeling for Ki-67, P53, pituitary transforming tumor gene (PTTG), and polysialic acid neural cell adhesion molecule) and transcriptomic (microarrays and q-RTPCR) methods with clinical data (post-surgical outcome with case–control statistical analysis), we found nine genes implicated in invasion (ADAMTS6, CRMP1, and DCAMKL3) proliferation (PTTG, ASK, CCNB1, AURKB, and CENPE), or pituitary differentiation (PITX1) showing differential expression in the three groups of tumors (P = 0.015 to 0.0001). A case–control analysis, comparing patients in remission (9 controls) and patients with persistent or recurrent tumors (14 cases) revealed that eight out of the nine genes were differentially up- or downregulated (P = 0.05 to 0.002), with only PTTG showing no correlation with clinical course (P = 0.258). These combined histological and transcriptomic analyses improve the pathological diagnosis of PRL tumors, indicating a reliable procedure for predicting tumor aggressiveness and recurrence potential. The similar gene profiles found between non-invasive human and benign rat tumors, as well as between aggressive–invasive human and malignant rat tumors provide new insights into malignancy in human pituitary tumors.Keywords
This publication has 18 references indexed in Scilit:
- What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and geneticsActa Endocrinologica, 2007
- Pituitary tumours: findings from whole genome analysesEndocrine-Related Cancer, 2006
- HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activityCancer Cell, 2006
- Common markers of proliferationNature Reviews Cancer, 2006
- Novel Molecular Signaling and Classification of Human Clinically Nonfunctional Pituitary Adenomas Identified by Gene Expression Profiling and Proteomic AnalysesCancer Research, 2005
- A Genetic Screen Identifies PITX1 as a Suppressor of RAS Activity and TumorigenicityCell, 2005
- Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistanceActa Neurochirurgica, 2005
- The ADAMTS metalloproteinasesBiochemical Journal, 2005
- Kinetochore Localization of Spindle Checkpoint Proteins: Who Controls Whom?Molecular Biology of the Cell, 2004
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002